A new drug with the active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI), the institute said on Saturday. The licence was issued in an expedited procedure.
The drug, which Egis started developing in April, could be used to treat coronavirus patients from mid-January. Favipiravir is the second drug, after remdesivir, that has been licenced by the OGYÉI to treat Covid-19 patients.
hungarymatters.hu
pixabay
